Insulin-Like Growth Factors (IGF)

Insulin-like growth factors are peptide hormones that play central roles in growth, development, and tissue homeostasis. The IGF system comprises two ligands (IGF-1 and IGF-2), two receptors (IGF-1R and IGF-2R), and six high-affinity binding proteins (IGFBP-1 through IGFBP-6) that regulate IGF bioavailability and half-life.

The name "insulin-like" reflects structural homology: IGF-1 shares approximately 50% amino acid sequence identity with proinsulin. Both signal through receptor tyrosine kinases, and at supraphysiological concentrations, IGF-1 can activate the insulin receptor (and vice versa). Despite this structural similarity, their biological roles are distinct — insulin primarily regulates acute metabolic responses, while IGFs drive long-term growth and tissue remodeling.

IGF-1: the GH effector

IGF-1 (70 amino acids) is the primary mediator of growth hormone's anabolic and growth-promoting effects. The "somatomedin hypothesis," first proposed in the 1950s and refined since, holds that GH stimulates hepatic production of IGF-1, which then acts on target tissues in an endocrine fashion.

Production and regulation

The liver produces approximately 75% of circulating IGF-1 in response to GH receptor activation. GH binding to its hepatic receptor activates the JAK2/STAT5 signaling pathway, directly upregulating IGF-1 gene transcription. Circulating IGF-1 feeds back to the hypothalamus and pituitary, suppressing GHRH and GH secretion — forming a classic negative feedback loop.

Nutritional status profoundly influences IGF-1 levels. Caloric restriction and protein deficiency reduce hepatic IGF-1 production even in the presence of adequate GH. This is why malnourished individuals have elevated GH but low IGF-1 — a state of GH resistance.

IGF-1 levels peak during puberty (corresponding to the pubertal growth spurt) and decline progressively with age, paralleling GH secretion decline.

IGF-1R signaling

IGF-1 binds the IGF-1 receptor (IGF-1R), a transmembrane receptor tyrosine kinase structurally related to the insulin receptor. Ligand binding triggers receptor autophosphorylation, activating two major downstream pathways:

• PI3K/AKT/mTOR pathway — drives protein synthesis, cell growth, and survival. AKT phosphorylates and inhibits pro-apoptotic proteins (BAD, FOXO transcription factors) while activating mTORC1, which promotes ribosomal biogenesis and translation initiation through S6K1 and 4E-BP1.
• RAS/MAPK/ERK pathway — promotes cell proliferation and differentiation. ERK signaling drives gene expression programs for cell cycle progression.

The PI3K/AKT/mTOR arm is predominantly responsible for IGF-1's anabolic effects in skeletal muscle, while both pathways contribute to its mitogenic and anti-apoptotic activity.

IGF-2: developmental growth factor

IGF-2 (67 amino acids) is structurally similar to IGF-1 but functionally distinct. It is the dominant growth factor during fetal development, with expression declining postnatally. IGF-2 is an imprinted gene — only the paternal allele is expressed, reflecting evolutionary parent-of-origin conflict over offspring growth.

IGF-2 signals through both IGF-1R (promoting growth) and the IGF-2R/mannose-6-phosphate receptor (which primarily clears IGF-2 from circulation rather than transducing growth signals). Loss of IGF-2 imprinting (biallelic expression) is associated with Beckwith-Wiedemann syndrome (overgrowth) and is observed in several cancers.

IGFBP regulation

The six IGFBPs are critical regulators of IGF bioavailability. In circulation, over 95% of IGF-1 is bound to IGFBPs — primarily in a ternary complex with IGFBP-3 and the acid-labile subunit (ALS). This complex extends IGF-1's half-life from approximately 10 minutes (free) to 12-16 hours (bound).

IGFBPs can both inhibit and potentiate IGF signaling depending on context:

• Inhibitory — sequestering IGFs from their receptors
• Potentiatory — IGFBP proteolysis (by PSA, matrix metalloproteinases, pregnancy-associated plasma protein-A) releases IGFs locally at tissue sites, concentrating their action

IGFBP-3 is GH-dependent and is used clinically as a marker of GH status. IGFBP-1 is insulin-regulated (suppressed by insulin, elevated during fasting), linking IGF bioavailability to metabolic state.

Role in muscle growth and repair

IGF-1 is a potent anabolic signal in skeletal muscle through multiple mechanisms:

• Myofiber hypertrophy — PI3K/AKT/mTOR activation increases protein synthesis rates, driving myofiber enlargement
• Satellite cell activation — IGF-1 promotes proliferation and differentiation of muscle satellite cells (adult muscle stem cells), supporting repair and adaptive hypertrophy
• Anti-catabolic effects — AKT phosphorylates and inactivates FOXO transcription factors, suppressing the ubiquitin-proteasome pathway (atrogin-1, MuRF1) and autophagy-lysosome degradation

Local IGF-1 expression in muscle (autocrine/paracrine IGF-1) is upregulated by resistance exercise and mechanical loading. This local production is distinct from hepatic endocrine IGF-1 and is considered the primary mediator of load-induced muscle hypertrophy.

IGF-1 LR3: an engineered analog

IGF-1 LR3 (Long R3 IGF-1) is a modified form of IGF-1 containing 83 amino acids: the glutamic acid at position 3 is replaced with arginine (R3), and a 13-amino-acid N-terminal extension peptide is added. These modifications dramatically reduce IGFBP binding — IGF-1 LR3 has less than 1% of native IGF-1's affinity for IGFBPs.

The result: IGF-1 LR3 has a much longer functional half-life in circulation (20-30 hours vs. minutes for free IGF-1) because it is not sequestered by binding proteins. It retains full IGF-1R binding and activation capacity. This makes it substantially more potent than native IGF-1 on a molar basis.

Mechano Growth Factor (MGF)

MGF is a splice variant of IGF-1 (the Ec splice variant in humans) produced locally in mechanically loaded muscle tissue. It contains a unique C-terminal E-domain peptide that distinguishes it from systemic IGF-1Ea. MGF appears to preferentially activate satellite cell proliferation rather than differentiation, positioning it as an early-phase repair signal following muscle damage. Synthetic MGF peptides (the isolated E-domain peptide) and PEGylated MGF (PEG-MGF, with improved half-life) are available as research compounds.

IGF system in disease

The dual nature of IGF signaling — promoting growth and survival — means the system is implicated in both deficiency and excess states. GH/IGF-1 deficiency causes growth retardation (dwarfism). Excess GH/IGF-1 causes acromegaly. Elevated circulating IGF-1 is epidemiologically associated with increased risk of several cancers (prostate, breast, colorectal), reflecting IGF-1R's anti-apoptotic and mitogenic signaling. Conversely, individuals with GH receptor deficiency (Laron syndrome) have very low IGF-1 and are virtually protected from cancer, though they have other health complications.

This dual nature demands careful consideration of the risk-benefit profile of any intervention that elevates IGF-1 signaling.